{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:39:05Z","timestamp":1792535945030,"version":"4.5.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"43","license":[{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T00:00:00Z","timestamp":1789344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82504169"],"award-info":[{"award-number":["82504169"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82574436"],"award-info":[{"award-number":["82574436"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Taishan Industrial Experts Program (to G.C.), the Jiangsu Provincial Basic Research Foundation"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,11,11]]},"DOI":"10.1038\/s41388-026-03987-3","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T17:45:21Z","timestamp":1789407921000},"page":"4659-4672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the PRMT5-CBX8 axis overcomes dual barriers of CD8\u207a T cell exclusion and tumor stemness for sensitizing TNBC to anti-PD-1 therapy"],"prefix":"10.1038","volume":"45","author":[{"given":"Congcong","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Runkai","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaiming","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiqi","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinyin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanguan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8886-1873","authenticated-orcid":false,"given":"Guo","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4305-9750","authenticated-orcid":false,"given":"Liyan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0716-3924","authenticated-orcid":false,"given":"Xun","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5114-3518","authenticated-orcid":false,"given":"Danyang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5294-9360","authenticated-orcid":false,"given":"Guoqin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,14]]},"reference":[{"key":"3987_CR1","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre RA, Goetz MP. Advances in systemic therapies for triple negative breast cancer. BMJ. 2023;381:e071674.","journal-title":"BMJ"},{"key":"3987_CR2","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini G, De Angelis C, Licata L, Gianni L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat Rev Clin Oncol. 2022;19:91\u2013113.","journal-title":"Nat Rev Clin Oncol"},{"key":"3987_CR3","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.1001\/jamaoncol.2024.3456","volume":"10","author":"G Villacampa","year":"2024","unstructured":"Villacampa G, Navarro V, Matikas A, Ribeiro JM, Schettini F, Tolosa P, et al. Neoadjuvant immune checkpoint inhibitors plus chemotherapy in early breast cancer: a systematic review and meta-analysis. JAMA Oncol. 2024;10:1331\u201341.","journal-title":"JAMA Oncol"},{"key":"3987_CR4","doi-asserted-by":"publisher","first-page":"2086","DOI":"10.1002\/cncr.31272","volume":"124","author":"MJ Kwa","year":"2018","unstructured":"Kwa MJ, Adams S. Checkpoint inhibitors in triple-negative breast cancer (TNBC): Where to go from here. Cancer. 2018;124:2086\u2013103.","journal-title":"Cancer"},{"key":"3987_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cac2.12539","volume":"44","author":"GR Khosravi","year":"2024","unstructured":"Khosravi GR, Mostafavi S, Bastan S, Ebrahimi N, Gharibvand RS, Eskandari N. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun (Lond). 2024;44:521\u201353.","journal-title":"Cancer Commun (Lond)"},{"key":"3987_CR6","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13045-023-01453-1","volume":"16","author":"L Yang","year":"2023","unstructured":"Yang L, Chu Z, Liu M, Zou Q, Li J, Liu Q, et al. Amino acid metabolism in immune cells: essential regulators of the effector functions, and promising opportunities to enhance cancer immunotherapy. J Hematol Oncol. 2023;16:59.","journal-title":"J Hematol Oncol"},{"key":"3987_CR7","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1038\/s41577-024-01026-4","volume":"24","author":"M De Martino","year":"2024","unstructured":"De Martino M, Rathmell JC, Galluzzi L, Vanpouille-Box C. Cancer cell metabolism and antitumour immunity. Nat Rev Immunol. 2024;24:654\u201369.","journal-title":"Nat Rev Immunol"},{"key":"3987_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217076","volume":"597","author":"Y Liu","year":"2024","unstructured":"Liu Y, Zhao Y, Song H, Li Y, Liu Z, Ye Z, et al. Metabolic reprogramming in tumor immune microenvironment: Impact on immune cell function and therapeutic implications. Cancer Lett. 2024;597:217076.","journal-title":"Cancer Lett"},{"key":"3987_CR9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1038\/s42255-020-0174-0","volume":"2","author":"B Huang","year":"2020","unstructured":"Huang B, Song BL, Xu C. Cholesterol metabolism in cancer: mechanisms and therapeutic opportunities. Nat Metab. 2020;2:132\u201341.","journal-title":"Nat Metab"},{"key":"3987_CR10","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1038\/s41423-022-00872-3","volume":"19","author":"W Tang","year":"2022","unstructured":"Tang W, Zhou J, Yang W, Feng Y, Wu H, Mok MTS, et al. Aberrant cholesterol metabolic signaling impairs antitumor immunosurveillance through natural killer T cell dysfunction in obese liver. Cell Mol Immunol. 2022;19:834\u201347.","journal-title":"Cell Mol Immunol"},{"key":"3987_CR11","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1158\/2159-8290.CD-24-0199","volume":"15","author":"A Bleve","year":"2025","unstructured":"Bleve A, Incerti M, Consonni FM, Garlatti V, Ballerini G, Pandolfo C, et al. ROR\u03b3 Bridges Cancer-Driven Lipid Dysmetabolism and Myeloid Immunosuppression. Cancer Discov. 2025;15:1505\u201325.","journal-title":"Cancer Discov"},{"key":"3987_CR12","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/s13046-024-03011-0","volume":"43","author":"J Dong","year":"2024","unstructured":"Dong J, Kong L, Wang S, Xia M, Zhang Y, Wu J, et al. Oncolytic adenovirus encoding apolipoprotein A1 suppresses metastasis of triple-negative breast cancer in mice. J Exp Clin Cancer Res. 2024;43:102.","journal-title":"J Exp Clin Cancer Res"},{"key":"3987_CR13","doi-asserted-by":"publisher","first-page":"48865","DOI":"10.1074\/jbc.M409699200","volume":"279","author":"S Benjannet","year":"2004","unstructured":"Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, et al. NARC-1\/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem. 2004;279:48865\u201375.","journal-title":"J Biol Chem"},{"key":"3987_CR14","doi-asserted-by":"publisher","first-page":"2995","DOI":"10.1172\/JCI29383","volume":"116","author":"TA Lagace","year":"2006","unstructured":"Lagace TA, Curtis DE, Garuti R, McNutt MC, Park SW, Prather HB, et al. Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice. J Clin Invest. 2006;116:2995\u20133005.","journal-title":"J Clin Invest"},{"key":"3987_CR15","doi-asserted-by":"publisher","first-page":"18602","DOI":"10.1074\/jbc.M702027200","volume":"282","author":"DW Zhang","year":"2007","unstructured":"Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, et al. Binding of proprotein convertase subtilisin\/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem. 2007;282:18602\u201312.","journal-title":"J Biol Chem"},{"key":"3987_CR16","doi-asserted-by":"publisher","first-page":"28856","DOI":"10.1074\/jbc.M109.037085","volume":"284","author":"S Poirier","year":"2009","unstructured":"Poirier S, Mayer G, Poupon V, McPherson PS, Desjardins R, Ly K, et al. Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route. J Biol Chem. 2009;284:28856\u201364.","journal-title":"J Biol Chem"},{"key":"3987_CR17","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1038\/s41586-020-2911-7","volume":"588","author":"X Liu","year":"2020","unstructured":"Liu X, Bao X, Hu M, Chang H, Jiao M, Cheng J, et al. Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. Nature. 2020;588:693\u20138.","journal-title":"Nature"},{"key":"3987_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156064","volume":"163","author":"A Ajoolabady","year":"2025","unstructured":"Ajoolabady A, Pratico D, Mazidi M, Davies IG, Lip GYH, Seidah N, et al. PCSK9 in metabolism and diseases. Metabolism. 2025;163:156064.","journal-title":"Metabolism"},{"key":"3987_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.101016","volume":"72","author":"Y Zhu","year":"2024","unstructured":"Zhu Y, Xia T, Chen DQ, Xiong X, Shi L, Zuo Y, et al. Promising role of protein arginine methyltransferases in overcoming anti-cancer drug resistance. Drug Resist Updat. 2024;72:101016.","journal-title":"Drug Resist Updat"},{"key":"3987_CR20","doi-asserted-by":"crossref","unstructured":"Yan W, Liu X, Qiu X, Zhang X, Chen J, Xiao K et al. PRMT5-mediated FUBP1 methylation accelerates prostate cancer progression. J Clin Invest. 2024, 134.","DOI":"10.1172\/JCI175023"},{"key":"3987_CR21","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41556-025-01610-3","volume":"27","author":"Y Fan","year":"2025","unstructured":"Fan Y, Wang Y, Dan W, Zhang Y, Nie L, Ma Z, et al. PRMT5-mediated arginine methylation stabilizes GPX4 to suppress ferroptosis in cancer. Nat Cell Biol. 2025;27:641\u201353.","journal-title":"Nat Cell Biol"},{"key":"3987_CR22","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1158\/0008-5472.CAN-23-1899","volume":"84","author":"Y Xu","year":"2024","unstructured":"Xu Y, Li X, Zhang S, Tang M, Yu R, Liao X, et al. CircMMP2(6,7) Cooperates with \u03b2-Catenin and PRMT5 to Disrupt Bone Homeostasis and Promote Breast Cancer Bone Metastasis. Cancer Res. 2024;84:328\u201343.","journal-title":"Cancer Res"},{"key":"3987_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05803-2","volume":"14","author":"C Chen","year":"2023","unstructured":"Chen C, Yang Y, Guo Y, He J, Chen Z, Qiu S, et al. CYP1B1 inhibits ferroptosis and induces anti-PD-1 resistance by degrading ACSL4 in colorectal cancer. Cell Death Dis. 2023;14:271.","journal-title":"Cell Death Dis"},{"key":"3987_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2024.103350","volume":"76","author":"X Xie","year":"2024","unstructured":"Xie X, Chen C, Wang C, Guo Y, Sun B, Tian J, et al. Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors. Redox Biol. 2024;76:103350.","journal-title":"Redox Biol"},{"key":"3987_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217271","volume":"604","author":"L Yu","year":"2024","unstructured":"Yu L, Wei W, Lv J, Lu Y, Wang Z, Cai C. FABP4-mediated lipid metabolism promotes TNBC progression and breast cancer stem cell activity. Cancer Lett. 2024;604:217271.","journal-title":"Cancer Lett"},{"key":"3987_CR26","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev-pharmtox-031023-100609","volume":"64","author":"E Tasdighi","year":"2024","unstructured":"Tasdighi E, Adhikari R, Almaadawy O, Leucker TM, Blaha MJ. LP(a): Structure, Genetics, Associated Cardiovascular Risk, and Emerging Therapeutics. Annu Rev Pharmacol Toxicol. 2024;64:135\u201357.","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"3987_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202501623","volume":"12","author":"QL Wang","year":"2025","unstructured":"Wang QL, Chen Z, Lu X, Lin H, Feng H, Weng N, et al. Methionine Metabolism Dictates PCSK9 Expression and Antitumor Potency of PD-1 Blockade in MSS Colorectal Cancer. Adv Sci (Weinh). 2025;12:e2501623.","journal-title":"Adv Sci (Weinh)"},{"key":"3987_CR28","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41594-024-01457-6","volume":"32","author":"M Uckelmann","year":"2025","unstructured":"Uckelmann M, Levina V, Taveneau C, Ng XH, Pandey V, Martinez J, et al. Dynamic PRC1-CBX8 stabilizes a porous structure of chromatin condensates. Nat Struct Mol Biol. 2025;32:520\u201330.","journal-title":"Nat Struct Mol Biol"},{"key":"3987_CR29","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1158\/0008-5472.CAN-17-0700","volume":"78","author":"CZ Zhang","year":"2018","unstructured":"Zhang CZ, Chen SL, Wang CH, He YF, Yang X, Xie D, et al. CBX8 Exhibits Oncogenic Activity via AKT\/\u03b2-Catenin Activation in Hepatocellular Carcinoma. Cancer Res. 2018;78:51\u201363.","journal-title":"Cancer Res"},{"key":"3987_CR30","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05706-2","volume":"14","author":"N Wang","year":"2023","unstructured":"Wang N, Li T, Liu W, Lin J, Zhang K, Li Z, et al. USP7- and PRMT5-dependent G3BP2 stabilization drives de novo lipogenesis and tumorigenesis of HNSC. Cell Death Dis. 2023;14:182.","journal-title":"Cell Death Dis"},{"key":"3987_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41590-017-0003-0","volume":"19","author":"S Liu","year":"2018","unstructured":"Liu S, Jiang M, Wang W, Liu W, Song X, Ma Z, et al. Nuclear RNF2 inhibits interferon function by promoting K33-linked STAT1 disassociation from DNA. Nat Immunol. 2018;19:41\u201352.","journal-title":"Nat Immunol"},{"key":"3987_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-023-05923-9","volume":"14","author":"J Huang","year":"2023","unstructured":"Huang J, Yu Z, Li X, Yang M, Fang Q, Li Z, et al. E3 ligase HECTD3 promotes RNA virus replication and virus-induced inflammation via K33-linked polyubiquitination of PKR. Cell Death Dis. 2023;14:396.","journal-title":"Cell Death Dis"},{"key":"3987_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-1288-0","volume":"10","author":"B Tang","year":"2019","unstructured":"Tang B, Tian Y, Liao Y, Li Z, Yu S, Su H, et al. CBX8 exhibits oncogenic properties and serves as a prognostic factor in hepatocellular carcinoma. Cell Death Dis. 2019;10:52.","journal-title":"Cell Death Dis"},{"key":"3987_CR34","doi-asserted-by":"crossref","unstructured":"Ng L, Li HS, Man AT, Chow AK, Foo DC, Lo OS et al. High expression of a cancer stemness-related gene, chromobox 8 (CBX8), in normal tissue adjacent to the tumor (NAT) is associated with poor prognosis of colorectal cancer patients. Cells. 2022;11:1852.","DOI":"10.3390\/cells11111852"},{"key":"3987_CR35","doi-asserted-by":"publisher","first-page":"690","DOI":"10.2174\/1574888X18666221014144642","volume":"18","author":"SK Razavi-Amoli","year":"2023","unstructured":"Razavi-Amoli SK, Omrani-Nava V, Heydari K, Kaidarova D, Alizadeh-Navaei R. LGR5 as a potential therapeutic target for breast cancer: a systematic review and meta-analysis. Curr Stem Cell Res Ther. 2023;18:690\u20138.","journal-title":"Curr Stem Cell Res Ther"},{"key":"3987_CR36","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1038\/s41417-021-00311-x","volume":"29","author":"E Sami","year":"2022","unstructured":"Sami E, Bogan D, Molinolo A, Koziol J, ElShamy WM. The molecular underpinning of geminin-overexpressing triple-negative breast cancer cells homing specifically to lungs. Cancer Gene Ther. 2022;29:304\u201325.","journal-title":"Cancer Gene Ther"},{"key":"3987_CR37","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s10555-024-10239-x","volume":"44","author":"W Wang","year":"2025","unstructured":"Wang W, Lokman NA, Barry SC, Oehler MK, Ricciardelli C. LGR5: An emerging therapeutic target for cancer metastasis and chemotherapy resistance. Cancer Metastasis Rev. 2025;44:23.","journal-title":"Cancer Metastasis Rev"},{"key":"3987_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s13046-025-03394-8","volume":"44","author":"S Imani","year":"2025","unstructured":"Imani S, Farghadani R, Roozitalab G, Maghsoudloo M, Emadi M, Moradi A, et al. Reprogramming the breast tumor immune microenvironment: cold-to-hot transition for enhanced immunotherapy. J Exp Clin Cancer Res. 2025;44:131.","journal-title":"J Exp Clin Cancer Res"},{"key":"3987_CR39","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/s41420-025-02682-8","volume":"11","author":"L Liu","year":"2025","unstructured":"Liu L, Wu D, Qian Z, Jiang Y, You Y, Wang Y, et al. Empowering hypoxia to convert cold tumors into hot tumors for breast cancer immunotherapy. Cell Death Discov. 2025;11:381.","journal-title":"Cell Death Discov"},{"key":"3987_CR40","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202408514","volume":"12","author":"T Li","year":"2025","unstructured":"Li T, Wu R, Luo KQ. PCSK9 Promotes the Malignancy of Triple-negative Breast Cancer Cells by Reducing Cholesterol Levels at the Plasma Membrane to Activate EGFR and HER3. Adv Sci (Weinh). 2025;12:e2408514.","journal-title":"Adv Sci (Weinh)"},{"key":"3987_CR41","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1038\/s41586-025-09017-8","volume":"643","author":"G Rademaker","year":"2025","unstructured":"Rademaker G, Hernandez GA, Seo Y, Dahal S, Miller-Phillips L, Li AL, et al. PCSK9 drives sterol-dependent metastatic organ choice in pancreatic cancer. Nature. 2025;643:1381\u201390.","journal-title":"Nature"},{"key":"3987_CR42","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1002\/cac2.70038","volume":"45","author":"M Lao","year":"2025","unstructured":"Lao M, Zhang X, Li Z, Sun K, Yang H, Wang S, et al. Lipid metabolism reprograming by SREBP1-PCSK9 targeting sensitizes pancreatic cancer to immunochemotherapy. Cancer Commun (Lond). 2025;45:1010\u201337.","journal-title":"Cancer Commun (Lond)"},{"key":"3987_CR43","doi-asserted-by":"publisher","DOI":"10.15252\/embj.2023114558","volume":"42","author":"Y Sun","year":"2023","unstructured":"Sun Y, Jin X, Meng J, Guo F, Chen T, Zhao X, et al. MST2 methylation by PRMT5 inhibits Hippo signaling and promotes pancreatic cancer progression. EMBO J. 2023;42:e114558.","journal-title":"EMBO J"},{"key":"3987_CR44","doi-asserted-by":"crossref","unstructured":"Wang Z, Li R, Hou N, Zhang J, Wang T, Fan P et al. PRMT5 reduces immunotherapy efficacy in triple-negative breast cancer by methylating KEAP1 and inhibiting ferroptosis. J Immunother Cancer. 2023;11:e006890.","DOI":"10.1136\/jitc-2023-006890"},{"key":"3987_CR45","doi-asserted-by":"crossref","unstructured":"Chen S, Hou J, Jaffery R, Guerrero A, Fu R, Shi L et al. MTA-cooperative PRMT5 inhibitors enhance T cell-mediated antitumor activity in MTAP-loss tumors. J Immunother Cancer. 2024;12:e009600.","DOI":"10.1136\/jitc-2024-009600"},{"key":"3987_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.217214","volume":"602","author":"Q He","year":"2024","unstructured":"He Q, Zhang Y, Li W, Chen S, Xiong J, Zhao R, et al. Inhibition of PRMT5 moderately suppresses prostate cancer growth in vivo but enhances its response to immunotherapy. Cancer Lett. 2024;602:217214.","journal-title":"Cancer Lett"},{"key":"3987_CR47","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.chembiol.2021.10.003","volume":"29","author":"JL Suh","year":"2022","unstructured":"Suh JL, Bsteh D, Hart B, Si Y, Weaver TM, Pribitzer C, et al. Reprogramming CBX8-PRC1 function with a positive allosteric modulator. Cell Chem Biol. 2022;29:555\u2013571.e511.","journal-title":"Cell Chem Biol"},{"key":"3987_CR48","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02709-5","volume":"19","author":"F Zeng","year":"2021","unstructured":"Zeng F, Luo L, Li D, Guo J, Guo M. KPNA2 interaction with CBX8 contributes to the development and progression of bladder cancer by mediating the PRDM1\/c-FOS pathway. J Transl Med. 2021;19:112.","journal-title":"J Transl Med"},{"key":"3987_CR49","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1158\/2159-8290.CD-24-0887","volume":"15","author":"B Belmontes","year":"2025","unstructured":"Belmontes B, Slemmons KK, Su C, Liu S, Policheni AN, Moriguchi J, et al. AMG 193, a clinical stage MTA-cooperative PRMT5 inhibitor, drives antitumor activity preclinically and in patients with MTAP-deleted cancers. Cancer Discov. 2025;15:139\u201361.","journal-title":"Cancer Discov"},{"key":"3987_CR50","doi-asserted-by":"publisher","first-page":"2412","DOI":"10.1158\/2159-8290.CD-23-0669","volume":"13","author":"LD Engstrom","year":"2023","unstructured":"Engstrom LD, Aranda R, Waters L, Moya K, Bowcut V, Vegar L, et al. MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP-deleted cancer. Cancer Discov. 2023;13:2412\u201331.","journal-title":"Cancer Discov"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03987-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03987-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03987-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T22:02:27Z","timestamp":1792533747000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03987-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,14]]},"references-count":50,"journal-issue":{"issue":"43","published-print":{"date-parts":[[2026,11,11]]}},"alternative-id":["3987"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03987-3","relation":{},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,14]]},"assertion":[{"value":"27 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 September 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"All methods were performed in accordance with the relevant guidelines and regulations. Written informed consent was obtained from all patients and has been approved by the Institutional review board of Second Affiliated Hospital of Soochow University. Animal experiments were performed according to the Health Guide for the Care and Use of Laboratory Animals approved by the Institutional Animal Care and Use Committee of Soochow University (SUDA20241030A01).","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}}]}}